Announcement PDF ASX ANNOUNCEMENT INVESTOR PRESENTATION MELBOURNE (AUSTRALIA) 19 September 2024: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to release the attached presentation, which will be used by the Company’s Executive Chair and Chief Executive Officer, Thian Chew, at various investor meetings and seminars. This announcement was approved for release by Thian Chew, Chairman of the Board. ____________________________________________ Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate in discussions: https://investors.inviongroup.com/ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”. Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com CORPORATE PRESENTATION September 2024 ASX: IVX Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. 2 COMPANY HIGHLIGHTS INVION AT CLINICAL INFLECTION POINT 3 Clinical-stage life sciences company listed on the ASX that is developing Photosoft Patent-protected Photosoft is the Next-Gen Photodynamic Therapy (PDT) Positive Ph II prostate cancer results, ongoing Phase I/II skin cancer with other trials planned Focus on unmet medical needs (cancers & infectious diseases), including Asiancentric indications Collaboration with world-leading research institutes (e.g. Peter Mac, Hudson Institute) Targeted research programs funded by partners (i.e. Hanlim Pharma, Dr.inB) THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs There are several approved PDT treatments on the market, but Photosoft is a groundbreaking technology that overcomes many of their significant shortcomings & side effects Photosoft is a minimally invasive modality for treating cancer that specifically identifies and destroys cancer cells whilst leaving the rest of the body’s normal cells unharmed Photodynamic Therapy (PDT) consists of three elements: 1 Combines photosensitiser compound with lightinduced activation Generates reactive oxygen species (“ROS”) causing damage to only targeted cells 2 3 Direct cell death along with activation of immune response Light Necrosis Photosensitiser accumulation in tumour tissue 01 4 Cellular localisation Generation of reactive O2 02 03 Cellular damage 04 Cell death via 05 Apoptosis Autophagy TARGET DISEASES AND INDICATIONS PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES PRIMARY FOCUS: CANCER (INV043) ▪ Multiple cancer indications ▪ Ablation and activation of immune response ▪ Improved efficacy of immune checkpoint inhibitor (ICI) treatments when in combination ▪ Topical and systemic formulations ▪ Strong therapeutic profile Target Indications ▪ Non-melanoma skin cancer (topical) ▪ Prostate cancer (sublingual) ▪ Anogenital cancer (topical) ▪ Glioblastoma (GBM): studies undertaken and funded by Hanlim Pharma ▪ Solid tumour cancer TBD (IV) 5 INFECTIOUS DISEASES ▪ Broad spectrum antimicrobial activity against viruses, bacteria and fungi ▪ No known drug resistance (to address AMR) ▪ Commercially viable focus Target Indications ▪ Human Papilloma Virus (HPV): studies undertaken and funded by Dr.inB ▪ Oral antimicrobial: peri-implant mucositis ▪ Additional TBD BACKGROUND AND DEVELOPMENT PATHWAY Partnership with Peter Mac Potential in metastatic cancers Photosoft destroys ovarian cancer in vitro Partnership with Hudson Institute COVID-19 Lockdowns LAYING GROUNDWORK FOR MULTIPLE CLINICAL TRIALS Reverse merger into IVX PoC 2: Complete regression of TNBC PoC 3: INV043 significantly improves ICI therapy PoC 1: INV043 effective against multiple cancers INV043 effective against anal cancer SCC in vitro Australian patent granted covering INV043 Additional Indications* GMP manufacturing with IDT Australia Skin Cancer: Ph I/II Clinical Trial Prostate Cancer: Ph II Clinical Study (RMW funded) HPV: PoC Clinical Studies (Dr.inB funded) Pre-clinical for new API INV043 / Portfolio of new compounds GBM: PoC Preclinical Studies (Hanlim funded) Discovery/Pre-clinical for IVX-P02/P03 2013 … 6 2017 Phase Ib/II clinical trials 2021 2023 2024 2025 *Indicative timelines >2025 LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE IVX Photosensitiser for Cancer: INV043 Effective in regressing multiple types of cancer in vivo1 PhotosoftTM Photosoft is a portfolio of photosensitisers protected by over ten patent families. INV043 is one of the photosensitisers described in a patent first granted in 2023 (Australia) with IP protection extending until at least 2041 ~600x greater photoxicity than Talaporfin (widely used photosensitiser) Selectively absorbed by cancer cells and not healthy tissue Stimulate the body’s natural immune response Work additively with blockbuster ICI 2 drugs Non-toxic, safe and limited side effects at up to 100x therapeutic dose 7 1 In preclinical studies including with the Hudson Institute of Medical Research and Peter MacCallum Cancer Centre 2 Immune Checkpoint Inhibitor (ICI) therapies are part of the Immunotherapy market of cancer treatments RESULTS AND FINDINGS: CANCER Clinical & Preclinical Data PHASE II PROSTATE CANCER CLINICAL TRIAL USING INV043 PHASE II INVESTIGATOR-LED PROSTATE CANCER STUDY* Screening: Men between 50-80 years with ▪ Biopsy proven primary prostate cancer, or ▪ Primary prostate cancer diagnosed by PSMA-PET or MRI. 75 Patients originally planned 41 Patients enrolled 2nd cohort of 16 patients treated postCOVID (due to COVID19 disruptions) COVID-19 Lockdowns: 10 patients dropped out. Remaining treated but with inconsistent compliance and data collection Only data from 2nd cohort used PRIMARY ENDPOINT TREATMENT PROTOCOL To assess INV043 PDT treatment effectiveness using Response Evaluation Criteria in Solid Tumours (RECIST 1.1) Clinical trial participants underwent a total of 6 cycles of PDT treatment (monotherapy) over 9 weeks (3 rounds of 2 consecutive PDT cycles with 4-week interval before rounds). Each PDT cycle consisted of 2 steps. SECONDARY ENDPOINTS To assess safety and tolerability as well as further assessments on effectiveness using standard outcome measures 9 1st cohort of 25 patients enrolled Step 1: Sublingual administration of photosensitiser Step 2: ~15-20 hours after dosing, 25 min of 660 nm laser administered The treatment schedule consisted of two laser therapy cycles conducted over 2 consecutive days (e.g. Mon, Tue), followed by a fourweek interval. * RMW Cho Group funded study as previously disclosed to the market PHASE II PROSTATE STUDY RESULTS: SOLID SAFETY DATA NO SERIOUS ADVERSE EVENTS, ONLY MILD SIDE EFFECTS OBSERVED INV043: Safe and Well Tolerated INV043 appeared to be safe and well-tolerated when administered sublingually to patients over the 6 cycles of PDT treatments (based on findings from 2nd cohort of 16 treated participants): ▪ No serious adverse events, life-threatening treatment or emergent adverse events (TEAEs) ▪ No clinically significant changes in vital signs, ECGs, or clinical laboratory parameters reported on study ▪ All adverse events reported were mild In contrast, current treatment options (eg, radiotherapy, chemotherapy and surgery) carry risks of significant side effects such as incontinence, bowel dysfunction, erectile dysfunction and/or infertility1 No. of Occurrences of TEAEs # 10 Recorded Adverse Events 8 16 patients x 6 questionnaires = over 96 recordings During 6 After 4 2 0 Fever Fatigue Minor bleeding Pain Buzzing senation Sore Headache General shoulder soreness 1 https://www.pcf.org/about-prostate-cancer/prostate-cancer-side-effects/ Tingly Swelling sensation legs on tongue Minor itching prostate Metalic taste Pain Prostate area Excessing Atrial urinating fibrillation PHASE II PROSTATE STUDY RESULTS: PROMISING EFFICACY SIGNALS 40-44% RESPONSE RATE TO STANDALONE TREATMENT PSMA-PET1 Results Number of patients testing positive 20 15 44% response 10 INV043 Results 3 Months Post Treatment Patients (Cohort 2, n-=16) evaluated using PSMA-PET scan to detect prostate cancer: ▪ BEFORE: All 16 patients were positive before treatment. ▪ AFTER: 7 patients negative 3 months after treatment (~44% response), 9 patients were positive 5 0 Before treatment 3 months post treatment RECIST Response2 RECIST (Response Evaluation Criteria in Solid Tumours) Framework3 ▪ 40% patients showed a positive response 3 months post treatment o 1 showed complete regression (no detectable lesion) o 3 showed partial regression (>30% reduction in lesion size) ▪ 4 patients showed stable disease ▪ 2 patients showed disease progression (>30% increase in lesion size) 11 4 Number of patients Where possible, MRI scans taken pre and post treatment to measure lesion size in prostate2 Total Regression 3 2 1 0 Positive response Stable disease 1 PSMA PET-CT now routinely used in evaluation of prostate cancer in context of primary staging and suspected tumour recurrence (Combes AD, 2022). It employs a radioactive substance that targets a protein called PSMA (prostate-specific membrane antigen) which is expressed by prostate cancer cells. 2 Two had received a prostatectomy prior to the photodynamic treatment and were excluded. Four patients did not have MRI scans for various reasons (such as the presence of implants) and were excluded from the assessment. 3 https://recist.eortc.org Disease progression THERAGNOSTIC POTENTIAL MULTIPLE CANCERS, PRECISION CANCER TARGETING, PROTECTIVE IMMUNITY SELECTIVE TARGETING Treated Control PROTECTIVE IMMUNITY https://inviongroup.com/videos-reports/ • INV043 selectively retained in malignant but not healthy tissue, across multiple cancers (incl. pancreatic, triplenegative breast, T-cell lymphoma in vivo) • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies • Minimises collateral damage to healthy organ tissues with no notable toxicity issues • Hudson Institute proof-of-concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment • INV043 has both fluorescence as well as ablation characteristics (under different wavelengths of light) • Tumour mass undetectable two weeks after initial treatment and no scarring evident • Applications in both diagnostic (405nm) and therapeutic use (660nm) – theragnostic potential • No recurrence of disease, re-challenge with TNBC implant could not re-establish new tumours, suggesting development of protective immunity 12 1 Adapted from https://www.nature.com/articles/s41598-023-30256-0#citeas, using chlorin e6 photosensitizer. The research activities involving the use of animals were carried out in accordance with relevant guidelines and regulations as well as with appropriate Animal Ethics Committee approval. COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as 12.5% 1 • Independent in vivo studies showed combined INV043 and anti-PD-1 therapies achieved 80% tumour elimination HUDSON INSTITUTE:. ~65% IMPROVEMENT IN TUMOUR VOLUME (TRIPLE NEGATIVE BREAST CANCER, INTRATUMORAL)2 PETER MAC: ~80% RESPONSE RATE (ANAL SCC CANCER, TOPICAL)3 ▪ 4T1 breast tumours treated using a restricted INV043 PDT protocol (intratumoural) and / or anti PD-1 antibody (intratumoral) ▪ Anal Squamous Cell Carcinoma (ASCC) tumours treated using a restricted INV043 PDT protocol (topical) and / or anti PD-1 antibody ▪ Monotherapies restricted tumour growth vs untreated controls ▪ Monotherapies restricted tumour growth vs untreated controls, with standalone INV043 showing lower tumour volume vs ICI alone ▪ Combination therapy regressed and stabilized tumours and achieved a ~65% reduction in tumour size at endpoint (n=4/group) ▪ Combination therapy resulted in 80% tumour-free subjective at endpoint (n=8-10/group) 7/10, no measurable tumour. 8th mouse histology, no evidence of tumour cells ** Combi therapy: ~65% improvement in effectiveness vs. ICI alone * *** INV043+PD1 vs Vehicle = p=0.001 ** INV043+PD1 vs PD1 p=0.0037 * INV043 vs Vehicle p=0.0397 13 1 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2762389 2 https://announcements.asx.com.au/asxpdf/20220530/pdf/459ffkjbvdpjrg.pdf 3 Per ASX announcement 4 March 2024 *** TREATMENT OPTIONS: FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY INV043 can be administered to multiple target indications via different drug and light delivery options ROUTES OF DRUG ADMINISTRATION 14 TOPICAL INTRAVENOUS INTRATUMORAL SUBLINGUAL LIGHT ADMINISTRATION OPTIONS TOPICALLY (LASER/LED) WITH OPEN SURGERY ENDOSCOPICALLY KEYHOLE SURGERY MULTIPLE POTENTIAL TARGETS TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA (CALENDAR YEAR) 1H2024 2H2024 1H2025 2H2025 >CY26 CANCER1 Follow up and monitoring Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Anogenital Cancers (Topical) Glioblastoma (Funded by Hanlim) Prostate Cancer (Funded by RMWC) Completed INFECTIOUS DISEASES HPV (Funded by Dr.inB) Oral Microbial (Peri-Implant Mucositis)3 PreClinical 15 Phase 1 1 Cancer is the key area of focus for Invion Phase 1b/2 2 The Phase I/II NMSC trial uses an adaptive study design means recruitment numbers and timelines may change to accelerate the evaluation of INV043 3 Timing subject to ongoing dialog with US FDA to determine pre-clinical requirements WHY SKIN CANCER? ATTRACTIVE CLINICAL TRIAL INDICATION Relatively Cost Effective Costs to undertake skin cancer trials typically lower than for other routes of administration (eg, intravenous) Faster Path to Market Trials with topical treatments often quicker to complete due to fewer safety concerns and effects can be more readily observed Synergies with Other Studies Safety data from same topical formulation may enable a faster path to a Phase II trial for anogenital cancers Large Attractive Market One of the world’s most common cancers with the skin cancer treatment market expected to hit US$18.1B in 2030 (7.7% CAGR1) Unmet Medical Need NMSC comprise 98% of all skin cancers and deaths exceed melanoma globally2 Standard of care can result in scarring and pain 16 1 https://finance.yahoo.com/news/skin-cancer-treatment-market-surpass-130500291.html 2 GLOBOCON 2020, WHO EVALUATION OF NMSC THERAPIES1 POTENTIAL TO DISPLACE STANDARD OF CARE Non-Melanoma Skin Cancer (NMSC) Phase I/II Clinical Trial (Adaptive Trial Structure): Addressing the unmet need for one of the world’s most common cancers2 GOOD INV043 (Topical) Metvix#/ALA PDT Treatment COSMETIC RESULT #by Galderma S.A. Cryosurgery Curettage & Electrodesiccation Excisional Surgery POOR FAIR 1 Based on management views 17 Mohs Surgery EFFECTIVENESS * https://www.aad.org/news/guidelines-to-treat-nonmelanoma-skin-cancer * https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746716/ * https://amp.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html 2 https://amp.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html GOOD Less Pain/ Discomfort More Pain/ Discomfort) CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, making affordability even harder for the majority of the world’s patients. Trends towards personalised medicines and targeted therapies (e.g. CAR T / cell therapies, immunotherapies, antibody drug conjugates which can cost US$100-500k2), Half of new drugs are orphan3, which cost 5.5 times more than non-orphan4 Commercial Rationale for Photosoft Works across multiple cancers without need to personalise – precision with less complexity INV043 is a small molecule based therapy that is highly scalable Photosoft solution has lower development and manufacturing costs Equipment and treatment process is not complex - helps reach a larger patient base 1 https://www.reuters.com/business/healthcare-pharmaceuticals/prices-new-us-drugs-rose-35-2023-more-than-previous-year-2024-02-23/ 18 2 https://www.mdpi.com/1999-4923/15/6/1761#:~:text=Additionally%2C%20the%20cost%20of%20ADC,a%20barrier%20for%20some%20patients 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290406/#:~:text=There%20has%20been%20significant%20policy,being%20approved%20in%20recent%20years 4 https://www.mdpi.com/1999-4923/15/6/1761#:~:text=Additionally%2C%20the%20cost%20of%20ADC,a%20barrier%20for%20some%20patients FUTURE ADDITIONAL INDICATIONS ADDRESSING UNMET NEEDS OF ASIAN-CENTRIC CANCERS, A US$40B MARKET5 Asians comprise 6% of clinical trial patients in FDA approved drugs2 … yet 60% of the world is Asian UNDER-REPRESENTATION IN DRUG DEVELOPMENT Ethnic Breakdown of Clinical Trials for 2020 Approved Drugs2 11% Hispanic 6% Asian MISMATCH WITH GLOBAL INCIDENCE Nasopharyngeal Cancer 86.0%1 cases in Asia, esp. China, HK Oral Cancer 65.8%1 cases in Asia esp. India, Indonesia, Pakistan 8% Black Oesophageal Cancer 79.7%1 cases in Asia esp. in east Asians Liver Cancer 72.5%1 cases in Asia mainly in China 75% White 1 https://gco.iarc.fr/today/fact-sheets-cancers GLOBOCON 2020 Non-Smoker Lung Cancer 60-80% women in Asia with lung cancer are non-smokers3 (esp. China). Highest among Asian American females in US4 2 Source: Food and Drug Administration – 2020 Drug Trials Snapshots Summary 19 Stomach Cancer 75.3%1 cases in Asia, esp. Korea, Japan and China 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431055/#b12-ms117_p0375 4 https://med.stanford.edu/content/dam/sm/care/communityheathtalk/Stanford-Community-Health-Talk-LCINF-FANS-2-21-2022.pdf 5 Oncology Drugs - Asia | Statista Market Forecast INFECTIOUS DISEASES Commercialisable Pipeline BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL ANTI-MICROBIAL TREATMENTS – WITHOUT RESISTANCE “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” World Health Organisation1 Leading Institutions: Viroclinics conducted virus tests & ACARE (University of Adelaide) conducted bacteria and fungi tests 100 % Inhibition Broad Spectrum Potential: In vitro tests showed PhotosoftTM to be effective against several types of pathogens, including antibiotic-resistant superbugs SARS-CoV-2: Omicron Selected PhotosoftTM Compounds vs. Remdesivir PhotosoftTM compounds 80 60 40 20 Remdesivir 0 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 Concentration µM Need for New Treatment Options: Potential for PhotosoftTM as a new treatment class for polymicrobial infections and/or where pathogens cannot develop drug resistance Broad Spectrum Activity: Minimum Inhibition Concentration (MIC50) of Selected Photosoft Compound following exposure to light for 5 minutes 30 25 Candida albicans VDLF1642 MIC Candida albicans ATCC 90028 MIC 1 https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance 0 Gram-negative (E. coli ATCC 35218) MIC 21 ” 5 Gram-negative (E. coli ATCC 25922) MIC Prof Darren J. Trott, Director, Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide 10 Gram-positive (ATCC 43300) [MRSA] MIC Given the general mode of action of PDT… it is unlikely for superbugs to develop resistance to the compounds 15 Gram-positive (USA300) [MRSA] MIC “ µM 20 1 TARGET ANTIMICROBIAL INDICATIONS COST EFFECTIVE AND ACCELERATED PATHS TO CLINICAL TRIALS HPV PROGRAM FUNDED BY DR.INB PERIODONTAL DISEASE HPV distribution profile in women 1 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Southern Africa Asia Eastern Europe Western Europe Addressing a Growing Unmet Need Collaboration • Per CDC, 47.2% in US >30 years, have a form of periodontal disease, increasing 70.1% of those >65 years2 • Undertake and fund to Proof-of-Concept clinical trials to test patient safety and efficacy • Global periodontal market size US$ 9.1 billion in 2022, to reach ~US$ 24.4 billion by 20323 • Dr.inB is a leading developer of PDT treatments in South Korea backed by Hanlim Pharma. Co., Ltd. • 28-56% of implant patients develop peri-implantitis4, an inflammatory reaction, with loss of supporting bone around an implant • Collaboration provides accelerated pathway to demonstrate clinical potential of Photosoft in infectious diseases like HPV • PhotosoftTM PDT advantages • Invion retains all rights to Photosoft and any new IP from the collaboration 22 1 https://www.sciencedirect.com/science/article/abs/pii/S0264410X12010808 2 https://www.cdc.gov/oralhealth/conditions/periodontal-disease.html 3 https://www.futuremarketinsights.com/reports/periodontal- market#:~:text=Periodontal%20Market%20Size%20%2D%20Industry%20Outlook,billion%20by%20the%20year%202032 4 https://pubmed.ncbi.nlm.nih.gov/18724856/ and Carl E. Misch 4th Edition • No resistance development • Non-invasive treatment • Ease of application • Repeated treatment possible EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS THIAN CHEW EXECUTIVE CHAIRMAN & CEO • Co-Founder, Chronic Airway Therapeutics • Advisory Board, Stanford Medicine CARE • Executive Director, Goldman Sachs • Director, KPMG Consulting, Senior Manager KPMG • Adj. Prof. HKUST, MBA/MA Wharton School • Director Business Development, Starpharma • Program Manager, AusBiotech • Regulatory Affairs, Bayer CropScience • MBA Melb Business School, B. Applied Science RMIT DR AMY PRAWIRA MEDICAL CONSULTANT NICOLETTA MUNER REGULATORY AND CLINICAL DEVELOPMENT • Founder/CEO, Obatica Pty Ltd (engaged to assist with clinical trials) • 20+ years non-clinical and clinical drug development, quality, manufacturing, incl. EMA and US FDA approval • 12+ years in clinical oncology and trials • Investigator with experience in over 90 early phase clinical trials • Founder Canary Regulatory Affairs • Head, Cancer Trials and Research Unit, Prince of Wales Hospital (Sydney) • Global Regulatory Affairs, Clinuvel Pharmaceuticals • Pre-clinical and regulatory affairs, Pfizer KIM STEEL CLINICAL TRIAL MANAGEMENT DR SEBASTIAN MARCUCCIO MEDICINAL CHEMISTRY • 18+ years managing global and clinical drug and device studies from Phase 1-IV across 14 countries • 35+ years in pharmaceutical/organic chemistry drug discovery and development (co-inventor recent PDT patents) • Managing Director, SAPRO Consulting • Founder / Director Advanced Molecular Technologies • Project Director, Novotech • Previously in Pharmaceutical Chemicals Research, CSIRO • Project Manager, Pacific Clinical Research Group • Adj. Prof. La Trobe University, PhD Organic Chemistry ANU ALEXANDER BENNETT TECHNICAL ADVISOR, LIGHT DEVICES LOUISE WHITE MANUFACTURING AND QUALITY • 35+ years in R&D, manufacturing and commercialisation of scientific instrumentation incl. ISO certifications • GM Forensic Light Sources, Rofin Australia. 23 SCOTT CARPENTER PROGRAM DIRECTOR • Led Medical Light Source trial for PDT in skin cancers Peter MacCallum Cancer Centre • 35+ years in the pharmaceutical industry, 13 years in vaccine manufacturing, CSL, Partner SeerPharma • Experience in virology R&D, bacterial vaccines production, quality control and production planning • Registered auditor for APVMA For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com